A Randomized Phase II Trial of IL-2/IFN-alpha Plus Bevacizumab Versus IL-2/IFN-alpha in Metastatic Renal Cell Carcinoma (mRCC) - Danish Renal Cancer Group (DARENCA) Study-1.

Trial Profile

A Randomized Phase II Trial of IL-2/IFN-alpha Plus Bevacizumab Versus IL-2/IFN-alpha in Metastatic Renal Cell Carcinoma (mRCC) - Danish Renal Cancer Group (DARENCA) Study-1.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Jul 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Interferon alpha-2b; Interleukin-2
  • Indications Renal cell carcinoma
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 12 Jul 2017 This trial was completed in Denmark on 2017-05-31 according to European Clinical Trials Database record.
    • 30 Aug 2012 Planned End Date changed from 1 Dec 2012 to 1 Dec 2014 as reported by ClinicalTrials.gov.
    • 13 Jun 2011 New source identified: European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top